SciSparc Reaches Agreement for MitoCareX Sale
SciSparc is set to embark on an exciting journey by selling its stake in MitoCareX for $700,000 and exchanging its remaining shares for common stock in N2OFF, marking a significant strategic advancement.
Overview of the Transaction
SciSparc Ltd. (Nasdaq: SPRC), a renowned clinical-stage pharmaceutical company, recently announced the signing of a definitive agreement to divest its entire ownership in MitoCareX, a venture collaborating with Dr. Alon Silberman. MitoCareX is dedicated to innovating cancer therapeutics by targeting mitochondrial proteins. The full ownership will now transition to N2Off, Inc. (Nasdaq: NITO), a publicly traded company in the United States.
SciSparc presently holds a significant 52.73% of MitoCareX's share capital. Under the terms of the Securities Purchase and Exchange Agreement with N2OFF, SciSparc will sell 4,961 shares of MitoCareX, receiving $700,000 while exchanging the remaining shares for N2OFF stock.
Key Financial Details
The transaction stipulates that SciSparc and its co-sellers will obtain N2OFF common stock, yielding a 40% ownership of the company’s fully diluted capital stock. Furthermore, additional stock will be granted depending on achievement milestones that could account for as much as 25% of N2OFF's fully diluted capital stock.
Two main financial commitments accompany this agreement: SciSparc and its partners will share 30% of N2OFF’s financing proceeds over the next five years, potentially totaling up to $1.6 million. Post-closing, N2OFF has pledged to invest an additional $1 million in MitoCareX.
Leadership Continuity and Strategic Vision
Dr. Silberman will remain at the helm as CEO with a new employment agreement that provides him with a restricted stock grant of 5% in N2OFF, which will vest over a span of three years. Both the chairman of SciSparc's board, Mr. Amitay Weiss, and board member, Ms. Liat Sidi, also serve on the board of N2OFF, emphasizing the collaborative potential between the two firms.
About SciSparc Ltd.
SciSparc Ltd. is dedicated to advancing the development of cannabinoid-based pharmaceuticals. The company’s focus lies in innovative therapies addressing various medical conditions, including neurological disorders and chronic pain. Among its notable drug development programs are SCI-110 for Tourette Syndrome, SCI-160 aimed at pain treatment, and SCI-210 directed towards ASD and status epilepticus therapy.
Investment Opportunities and Market Impact
The divestiture of MitoCareX marks a pivotal moment for SciSparc. This decision aligns with the company's strategic initiative to refocus on its core competencies while securing additional capital to accelerate its ongoing and future drug development programs.
Long-Term Vision for Growth
With the transition of MitoCareX to N2OFF, SciSparc is positioned to enhance its growth trajectory while providing stakeholders with potential financial returns driven by strategic collaborations and investments in innovative therapeutics.
Frequently Asked Questions
What prompted SciSparc to sell MitoCareX?
The sale is part of SciSparc's strategy to focus on its core strengths and enhance its portfolio by generating capital.
What are the financial terms of the agreement?
SciSparc will receive $700,000 for 4,961 shares and common stock in N2OFF, with additional provisions linked to milestone achievements.
Who will lead MitoCareX after the acquisition?
Dr. Alon Silberman will continue as CEO of the newly acquired MitoCareX, under a revised employment agreement.
What is the primary focus of SciSparc's research?
SciSparc specializes in cannabinoid pharmaceuticals, targeting various conditions including neurological disorders and chronic pain.
How will the sale affect SciSparc's future?
The sale allows SciSparc to direct resources towards its current drug development pipeline and seek new growth opportunities.
